Table 3.

Subgroups efficacy and safety outcomes.

	MTA	ETOA	ETOA + EEA	p Value
	% (95%CI)	% (95%CI)	% (95%CI)
GTR	59.8 (49.5–70.2)	41.3 (11.6–70.9)	23.5 (0–52.5)	0.001
Recurrence	24.4 (19.4–29.4)	4.4 (0–11.2)	NA	0.014
Vision acuity improvement	57.3 (51–63.5)	69.2 (41.5–96.9)	51.3 (16.7–85.9)	0.902
Proptosis improvement	60 (47.4–72.6)	79.4 (57.3–100)	69.8 (37.0–100)	0.002
CN focal deficits	21 (14.5–27.6)	7.3 (0–18.1)	20.3 (0–46.7)	0.411
CSF leak	4.9 (2.8–6.9)	5 (0–11.6)	20.3 (0–46.7)	0.551
Other	13.6 (9.5–17.7)	15.4 (1.6–29.2)	NA	0.866
	WHO Grade I	WHO Grades I + II	WHO Grades I + II + III	p Value
	% (95%CI)	% (95%CI)	% (95%CI)
GTR	43.1 (20.4–65.9)	46.5 (26.8–66.1)	57.3 (47.5–67.1)	0.001
Recurrence	17.7 (1.6–33.9)	24.8 (14.9–34.7)	20.7 (16.6–24.8)	0.185
Vision acuity improvement	69.0 (47.6–90.4)	54.7 (41.1–68.3)	57.5 (51.7–63.3)	0.779
Proptosis improvement	77.3 (60.9–93.7)	74.0 (61.3–86.6)	79.3 (73.7–84.8)	0.013
CN focal deficits	12.4 (6.9–17.9)	15.4 (6.7–24.2)	20.6 (14.9–26.3)	0.224
CSF leak	5 (0–11.8)	5.2 (1.2–9.2)	3.9 (2.3–5.5)	0.983
Other	22.1 (5.1–39.2)	11.7 (6.5–16.8)	13.9 (10.1–17.7)	0.001
	Anatomical Class I	Anatomical Class I + II + III + IV		p Value
	% (95%CI)	% (95%CI)
GTR	78.6 (60.1–97.1)	57.3 (47.5–67.1)		0.001
Recurrence	15.1 (6.5–23.7)	20.7 (16.6–24.8)		0.001
Vision acuity improvement	71.5 (63.7–79.4)	57.5 (51.7–63.3)		0.003
Proptosis improvement	60.1 (38–82.2)	79.3 (73.7–84.8)		0.001